Supply–Demand Inversion and a Sentiment Rebound: CXO/CDMO Enters a New Expansion Cycle in H2 2026

H1 2026 A-share CXO revenue reached RMB 61.6B (+19.6%) with deducted non-net profit +58.2%; CDMO revenue RMB 52.9B (+21.4%) and Q2 growth accelerating to 27.2%. Backlog visibility at top players now spans 2–3 years, and global CXO financing hit US$26.75B (+58.5%) — three forces driving a new R&D and manufacturing expansion cycle.

In late Q3 2026, the CXO/CDMO industry reached a turning point: after the rapid upcycle of 2020–2023, the capacity build-out and the subsequent de-capacity cycle, the supply–demand relationship has inverted in substance. Earnings are accelerating, backlog visibility at top players has stretched to 2–3 years, and global financing is recovering — three forces pushing the industry into a new R&D and manufacturing expansion cycle. This article structures that inflection using H1 2026 public filings and multiple broker notes.

1. Earnings inflection confirmed: H1 sector revenue RMB 61.6B, deducted profit +58.2%

In H1 2026, the A-share CXO sector posted total revenue of RMB 61.6B, up 19.6% YoY; deducted non-net profit reached RMB 13.8B, up 58.2% YoY — profit growth well ahead of revenue, as margin leverage begins to release. The CDMO segment stood out: H1 revenue RMB 52.9B (+21.4% YoY), with Q2 growth accelerating to 27.2%, a segment gross margin of 45.6%, and healthy operating cash flow.

The CRO segment showed a divergent profit mix, with deducted net profit up 101.6% YoY, mainly on preclinical order repair and fading mark-to-market effects on biological assets. Multiple leaders raised full-year revenue guidance — WuXi AppTec and Pharmaron both lifted expectations, reflecting sharply improved visibility.

2. Backlog visibility: top players covered for 2–3 years

Orders are the leading indicator of CDMO sentiment. In H1 2026, backlog and new-order growth moved together at the leaders: WuXi AppTec's backlog reached RMB 66.43B (+25.2% YoY); Asymchem's new orders grew ~54% YoY and JOINN's +98%; WuXi XDC's uncompleted service orders rose ~50% YoY; Pharmaron's new orders grew >30%, with CDMO new orders >50%.

Broker notes widely note that backlog visibility at the leaders now spans 2–3 years, meaning the durability of this upcycle has order-level support rather than being a mere price recovery.

3. Three growth engines: ADC, peptides·GLP-1, bispecifics

The recovery is not uniform but driven by three clear modality threads. First, ADCs: WuXi Biologics disclosed 196 bispecific/multispecific programs (3 commercial) and 252 ADC programs (1 commercial); WuXi XDC, the global ADC-outsourcing leader, saw backlog up 50% YoY, directly benefiting from the global ADC boom. Second, peptides and GLP-1: Asymchem's peptide capacity is 45,000 L, expanding to 69,000 L by end-2026; the obesity-drug surge drives peptide R&D and manufacturing outsourcing, and oral GLP-1 commercial manufacturing agreements mark the shift from injectable to oral peptides. Third, bispecific/multispecific antibodies: WuXi Biologics' 196 such programs carry high technical barriers but outsized commercial value versus traditional mAbs.

Behind all three is one logic — the complex processes of emerging modalities (conjugation, highly potent synthesis, long-acting peptides) inherently require deep CRDMO involvement, and order conversion will progressively show up as revenue and profit.

4. Financing rebound: H1 global CXO financing US$26.75B, +58.5%

The source of demand is Biotech financing recovery. In H1 2026, global CXO-related financing reached US$26.75B (+58.5% YoY); China's share was US$5.81B (+79.1% YoY). Recovering Biotech financing advances pipelines, and outsourcing orders typically land 2–3 quarters later, forming a 'financing → pipeline → outsourcing' transmission chain.

5. Geopolitics and policy: expectations improving, support for origination

In early October, the US and Chinese heads of state reached an eight-point consensus proposing a 'constructive and stable US–China relationship based on respect, fairness and reciprocity', easing market pessimism over geopolitical disruptions such as the BIOSECURE Act. Meanwhile, the 15th Five-Year Plan sets a target of First-in-class drugs reaching >25% of the global total by 2030, shifting policy from cost control toward supporting original innovation and providing mid-to-long-term demand support for the innovative-drug value chain.

From de-capacity to a new expansion, the core of this CXO inflection is not a price rebound but an order-structure upgrade driven jointly by emerging-modality industrialization and global financing recovery. Whoever builds verifiable integrated CRDMO capability in multi-modality tech (ADC, peptides, bispecifics) will lead the next expansion cycle.